PharmaTimes presents Alantra’s annual look at the fastest-growing pharma companies
An exciting, futuristic chapter for clinical trials has opened in which participant engagementwill flourish, expansive data will navigate the maze of disease and digital technology will take pharma and patients to previously unexplored dimensions. John Pinching reports.
Steve How and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore some of the key aspirations of the NHS’ Long Term Plan
US regulators have placed a partial clinical hold on all trials assessing venetoclax for multiple myeloma after a higher than expected number of patient deaths.
19th March 2019
Scientists have developed and tested a vaccine that they say could be used to treat chronic pain caused by osteoarthritis.
19th March 2019
New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga.
18th March 2019
GW Pharmaceuticals is selling its rare paediatric disease priority review voucher (PRV) for $105 million to Biohaven Pharmaceutical.
18th March 2019
Shares in UK-based Allergy Therapeutics have taken a dive after the firm’s immunotherapy for birch pollen allergy failed to hit targets in a late-stage trial.
18th March 2019
The UK is well positioned to take advantage of virtual drug discovery services, says Medicines Discovery Catapult's Graeme Wilkinson
The pharma industry needs to transform the supply chain from a source of regulatory risk to a legitimate business opportunity.
Trouble on the horizon for pharma? A look at post-Brexit immigration.
The rise of virtual business models in biopharma reflects the changing face of the pharmaceutical industry - big pharma discovering and developing its own pipeline exclusively in-house no longer exists.
Richard Davies, vice president and solutions expert at CluePoints, says there’s “a huge opportunity” for operational efficiency gains in clinical trials
PharmaTimes talks to Lotte Bjerre Knudsen, inventor of diabetesdrug liraglutide and scientific vice president at Novo Nordisk
Ten months since sweeping data privacy laws came into force in Europe, pharma companies are wrestling with the new ‘right to be forgotten’
Dr Chris Doherty discusses the rise of clinical research organisations (CROs) from his vantage point as managing director at Alderley Park
An exciting, futuristic chapter for clinical trials has opened in which participant engagementwill flourish, expansive data will navigate the maze of disease and digital technology will take pharma and patients to previously unexplored dimensions. John Pinching reports.
How seven innovations are accelerating research and bringing new data-driven insights to the clinical trial landscape, potentially reducing the time and cost of drug development
PharmaTimes presents Alantra’s annual look at the fastest-growing pharma companies
Steve How and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore some of the key aspirations of the NHS’ Long Term Plan
How can big pharma and SME pharma work to mutual advantage and help patients with unmet medical need?
Richard Billington, chief technology officer of MatsSoft, explains how IT leaders can adapt to a patient-centric world
Sam Grove, commercial director at Oberoi Consulting, explains how pharma companies can better achieve their brand objectives with training on clinical systems intelligence.
Label – and label extension – strategy is starting to shift from a broader and broader focus to a very specific one
Across all industries, people are changing the ways they engage with products, services, and brands. View more...
Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW
